Sospecha de reacciones adversas a la vacuna triple vírica notificadas al Centro de Farmacovigilancia de la Comunidad Valenciana

Offit, 2008, Vaccine safety, 1629 Guideline on the conduct of pharmacovigilance for vaccines for pre- and post-exposure prophylaxis against infectious diseases, EMEA/CHMP/PhVWP/5034449/2007 (2009). Ley 29/2006, de 26 de julio, de garantías y uso racional de los medicamentos y productos sanitarios, BOE número 178, de 27 de julio (2006). Rodríguez, 2002, Farmacovigilancia, 575 De la Torre Misiego, 1999, Eradication of measles. Vaccination coverage in Spain, Rev Esp Salud Pública, 73, 617 Orden de 25 de noviembre de 1999, de la Conselleria de Sanitat, por la que se aprueba el nuevo calendario de vacunaciones sistemáticas infantiles en la Comunidad Valenciana, DOGV número 3661 de 1 de julio; 2000. Director General de Investigación y Salud Pública. Instrucciones de la Dirección General de Investigación y Salud Pública con relación al adelanto de la 1.a dosis de vacuna triple vírica de los 15 meses a los 12 meses. Dirección General de Investigación y Salud Pública. Conselleria de Sanitat, Generalitat Valenciana. Valencia. 2011. Strebel, 2008, Measles vaccine, 353 Jefferson, 2003, Unintended events following immunization with MMR: a systematic review, Vaccine, 21, 3954, 10.1016/S0264-410X(03)00271-8 Wakefield, 1998, Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children, Lancet, 351, 637, 10.1016/S0140-6736(97)11096-0 Picazo, 2011, Evidencias disponibles sobre la seguridad de las vacunas, Vacunas, 12, 3, 10.1016/S1576-9887(11)70002-4 [No authors listed]. Retraction ileal lymphoid nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet. 2010;375:445. Doja, 2006, Immunizations and autism: a review of the literature, Can J Neurol Sci, 33, 5, 10.1017/S031716710000528X Patja, 2000, Serious adverse events after measles-mumps-rubella vaccination during a fourteen-year prospective follow-up, Pediatr Infect Dis J, 19, 1127, 10.1097/00006454-200012000-00002 Peltola, 1986, Frequency of true adverse reactions to measles-mumps-rubella vaccine. A double-blind placebo-controlled trial in twins, Lancet, 1, 939, 10.1016/S0140-6736(86)91044-5 Barlow, 2001, The risk of seizures after receipt of whole-cell pertussis or measles, mumps, and rubella vaccine, N Engl J Med, 345, 656, 10.1056/NEJMoa003077 Nieminen, 1993, Acute thrombocytopenic purpura following measles, mumps and rubella vaccination. A report on 23 patients, Acta Paediatr, 82, 267, 10.1111/j.1651-2227.1993.tb12657.x Andrews, 2011, A collaborative approach to investigating the risk of thrombocytopenic purpura after measles-mumps-rubella vaccination in England and Denmark, Vaccine Sauve, 2010, Postvaccination thrombocytopenia in Canada, Pediatr Infect Dis J, 29, 559, 10.1097/INF.0b013e3181d2bb45 France, 2008, Risk of immune thrombocytopenic purpura after measles-mumps-rubella immunization in children, Pediatrics, 121, e687, 10.1542/peds.2007-1578 Rajantie, 2007, Vaccination associated thrombocytopenic purpura in children, Vaccine, 25, 1838, 10.1016/j.vaccine.2006.10.054 Rüger, 2010, Safety of two-dose regimen of a combined measles, mumps, rubella and varicella live vaccine (Proquad) manufactures with recombinant human albumin (rHA) Cerecedo Carballo, 2007, Safety of measles-mumps-rubella vaccine (MMR) in patients allergic to eggs, Allergol Immunopathol (Madr), 35, 105, 10.1157/13106778 Fina Avilés, 2007, Vacuna triple vírica y alergia al huevo. Experiencia en una unidad de vacunación hospitalaria, An Pediatr (Barc), 67, 362, 10.1016/S1695-4033(07)70654-9 Pool, 2002, Prevalence of anti-gelatin IgE antibodies in people with anaphylaxis after measles-mumps rubella vaccine in the United States, Pediatrics, 110, e71, 10.1542/peds.110.6.e71 Zhou, 2003, Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)-United States, 1991-2001, MMWR Surveill Summ, 52, 1 Plotkin, 2008, Mumps vaccine, 435 Plotkin, 2008, Rubella vaccine, 737